388 related articles for article (PubMed ID: 32125403)
1. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
2. Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.
San-Juan-Rodriguez A; Piro VM; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2021 Jan; 27(1):112-117. PubMed ID: 33377437
[No Abstract] [Full Text] [Related]
3. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
4. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
5. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
6. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
Mattingly TJ; Levy JF; Slejko JF; Onwudiwe NC; Perfetto EM
Pharmacoeconomics; 2018 Sep; 36(9):1093-1099. PubMed ID: 29752675
[TBL] [Abstract][Full Text] [Related]
7. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
8. Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019.
Dickson S; Gabriel N; Gellad WF; Hernandez I
JAMA Health Forum; 2023 Jun; 4(6):e231430. PubMed ID: 37327008
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
Dickson SR; Gabriel N; Gellad WF; Hernandez I
JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
[TBL] [Abstract][Full Text] [Related]
10. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
11. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
Kakani P; Chernew M; Chandra A
J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
[TBL] [Abstract][Full Text] [Related]
12. Net prices of new antiobesity medications.
Hernandez I; Sullivan SD
Obesity (Silver Spring); 2024 Mar; 32(3):472-475. PubMed ID: 38228492
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
14. Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
Sarpatwari A; Tessema FA; Zakarian M; Najafzadeh MN; Kesselheim AS
Health Aff (Millwood); 2021 May; 40(5):772-778. PubMed ID: 33939506
[TBL] [Abstract][Full Text] [Related]
15. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
16. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
17. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
18. Branded Price Variation in the United States Drug Market, 2010 to 2019.
Levy J; Ippolito B
Value Health; 2021 Sep; 24(9):1237-1240. PubMed ID: 34452701
[TBL] [Abstract][Full Text] [Related]
19. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
20. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
